Status: Recruiting
A Study to Evaluate the Impact of Renal Impairment on the Pharmacokinetics (PK) of Ribupatide
The primary objective of the study is to estimate the PK parameters of ribupatide in participants with severe renal impairment or end-stage kidney disease (ESKD) after a single dose of ribupatide subcutaneous (SC) injection compared with participants with normal renal function.
Participants needed: 32
Trial details
Phase: Phase 1Age: 18-85Biological sex: AllType: InterventionalSponsor: KaileraUpdated: Oct 1, 2026Locations: 2
Eligibility criteria
Body mass index ≥18.5 at Screening. [+3]
History or presence of clinically significant cardiovascular, pulmonary, hepatic... [+8]